NervGen Pharma (NASDAQ:NGEN) Posts Earnings Results, Beats Expectations By $999.07 EPS

NervGen Pharma (NASDAQ:NGEN) released its quarterly earnings data on Friday. The company reported $999.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $999.07, reports.

NervGen Pharma Trading Down 3.8%

NGEN traded down $0.14 during trading on Friday, reaching $3.57. The stock had a trading volume of 407,740 shares, compared to its average volume of 168,767. NervGen Pharma has a one year low of $1.50 and a one year high of $6.30.

Wall Street Analyst Weigh In

NGEN has been the subject of a number of analyst reports. HC Wainwright raised NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Weiss Ratings initiated coverage on NervGen Pharma in a research note on Friday, April 24th. They set a “sell (d-)” rating for the company. Wall Street Zen lowered NervGen Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday. Zacks Research raised NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, NervGen Pharma presently has an average rating of “Moderate Buy” and an average target price of $18.00.

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.